Please assess the completion status of the following clinical trial:

Trial Title: Phase 3 Study of Dienogest for the Treatment of Endometriosis in Chinese Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Women between 18 and 45 years of age, inclusive~* Women with endometriosis confirmed by laparoscopy or laparotomy within ten years but no later than 2 weeks before the Screening Visit~* A score of at least 30 on a 100 mm visual analog scale (VAS) for endometriosis-associated pelvic pain at Screening Visit and Baseline Visit~* Good general health (except for findings related to endometriosis, with or without infertility), as evidenced by medical history and complete physical and gynecological examination~* Willingness to use a barrier method of contraception is required~Exclusion Criteria:~* Pregnancy or lactation (less than three months since delivery, abortion, or lactation before start of treatment)~* Wish for pregnancy within intended treatment period~* Before menarche or after menopause~* Amenorrhea (more than three consecutive months in the six months before screening)~* Undiagnosed abnormal genital bleeding~* Previous/use of hormonal agents~* Any disease or condition that may worsen under hormonal treatment~* Signs and/or symptoms of therapy-resistant endometriosis despite more than one prior attempt at drug treatment or surgical therapy~* Need for primary surgical treatment of endometriosis~* Regular use of pain medication due to other underlying diseases~* Contra-indication for the supportive analgesic medication (ibuprofen)

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Dienogest (Type: EXPERIMENTAL): 50% of the participants will be randomized to this arm and will receive 2 mg dienogest (DNG) once daily by mouth from 0-52 weeks
- Placebo (Type: PLACEBO_COMPARATOR): 50% of the participants will be randomized to this arm and will receive placebo once daily by mouth from 0-24 weeks then switch to 2 mg dienogest (DNG) once daily by mouth from 25-52 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).